Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1

Phytomedicine

Volumn 21, Issue 3, 2014, Pages 323-332

  Tajima, Yasuhiro ^a   Nakagawa, Hiroshi ^a,b,c   Tamura, Ai ^b,c   Kadioglu, Onat ^d   Satake, Kazuhiro ^a   Mitani, Yuji ^a   Murase, Hayato ^a   Regasini, Luis Octavio ^e   Da Silva Bolzani, Vanderlan ^e   Ishikawa, Toshihisa ^b,f   Fricker, Gert ^c   Efferth, Thomas ^d  

^a CHUBU UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

ABCB1; ATP binding cassette (ABC) transporter; Guanidine alkaloid; P glycoprotein; Pterogyne nitens

Indexed keywords

ANTINEOPLASTIC AGENT; GALEGINE; GUANIDINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; NITENSIDINE A; NITROGEN; OXYGEN; PLANT EXTRACT; PTEROGYNIDINE; PTEROGYNINE; SULFUR; UNCLASSIFIED DRUG; VERAPAMIL; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ADENOSINE TRIPHOSPHATASE; CALCEIN; FLUORESCEIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; TERPENE;

ARTICLE; ATPASE ACTIVITY ASSAY; BINDING SITE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; FABACEAE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOLECULAR DOCKING; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PTEROGYNE NITENS; T LYMPHOBLAST; T LYMPHOCYTE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; ISOLATION AND PURIFICATION; LEUKEMIA, T-CELL; METABOLISM; MULTIDRUG RESISTANCE; PHYTOTHERAPY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

FABACEAE; PTEROGYNE NITENS; RUMEX;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FABACEAE; FLUORESCEINS; GUANIDINES; HUMANS; LEUKEMIA, T-CELL; MOLECULAR DOCKING SIMULATION; MONOTERPENES; P-GLYCOPROTEINS; PHYTOTHERAPY; PLANT EXTRACTS; STRUCTURE-ACTIVITY RELATIONSHIP; VERAPAMIL;

EID: 84896494467     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2013.08.024     Document Type: Article

References (36)

1. T. Adachi, H. Nakagawa, I. Chung, Y. Hagiya, K. Hoshijima, N. Noguchi, M.T. Kuo, and T. Ishikawa Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress J. Exp. Ther. Oncol. 6 2007 335 348
2. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, and G. Chang Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
3. C.J. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, M.M. Gottesman, and I.B. Roninson Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 47 1986 381 389
4. P. Chiba, G. Ecker, D. Schmid, J. Drach, B. Tell, S. Goldenberg, and V. Gekeler Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance Mol. Pharmacol. 49 1996 1122 1130
5. F.A. de Jong, M.J. de Jonge, J. Verweij, and R.H. Mathijssen Role of pharmacogenetics in irinotecan therapy Cancer Lett. 234 2006 90 106
6. M.J.S. Dewar, E.G. Zeobisch, E.F. Healy, and J.P. Stewart Development and use of quantum mechanical molecular models.76. AM1: a new general purpose quantum mechanical molecular model J. Am. Chem. Soc. 107 1985 3902 3909
7. R.A. Duarte, E.R. Mello, C. Araki, S. Bolzani Vda, D.H. Siqueira e Silva, L.O. Regasini, T.G. Silva, M.C. de Morais, V.F. Ximenes, and C.P. Soares Alkaloids extracted from Pterogyne nitens induce apoptosis in malignant breast cell line Tumour Biol. 31 2010 513 522
8. G. Ecker, M. Huber, D. Schmid, and P. Chiba The importance of a nitrogen atom in modulators of multidrug resistance Mol. Pharmacol. 56 1999 791 796
9. S. Ekins, R.B. Kim, B.F. Leake, A.H. Dantzig, E.G. Schuetz, L.B. Lan, K. Yasuda, R.L. Shepard, M.A. Winter, J.D. Schuetz, J.H. Wikel, and S.A. Wrighton Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates Mol. Pharmacol. 61 2002 974 981
10. D.C. Fernandes, L.O. Regasini, J.C. Vellosa, P.M. Pauletti, I. Castro-Gamboa, V.S. Bolzani, O.M. Oliveira, and D.H. Silva Myeloperoxidase inhibitory and radical scavenging activities of flavones from Pterogyne nitens Chem. Pharm. Bull. (Tokyo) 56 2008 723 726
11. A. Fiser, and A. Sali Modeller: generation and refinement of homology-based protein structure models Methods Enzymol. 374 2003 461 491
12. J.M. Ford Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers Eur. J. Cancer 32A 1996 991 1001
13. A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski Characterization of two pharmacophores on the multidrug transporter P-glycoprotein Mol. Pharmacol. 62 2002 1288 1298
14. C. Globisch, I.K. Pajeva, and M. Wiese Structure-activity relationships of a series of tariquidar analogues as multidrug resistance modulators Bioorg. Med. Chem. 14 2006 1588 1598
15. J.J. Gribar, M. Ramachandra, C.A. Hrycyna, S. Dey, and S.V. Ambudkar Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system J. Membr. Biol. 173 2000 203 214
16. T. Ishikawa Multidrug resistance: genomics of ABC transporters D.N. Cooper, Nature Encyclopedia of the Human Genome Vol. 4 2003 Nature Publishing Group London, UK 154 160
17. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1976 152 162
18. F. Kiefer, K. Arnold, M. Kunzli, L. Bordoli, and T. Schwede The SWISS-MODEL repository and associated resources Nucleic Acids Res. 37 2009 D387 D392
19. S. Kitagawa, T. Nabekura, T. Takahashi, Y. Nakamura, H. Sakamoto, H. Tano, M. Hirai, and G. Tsukahara Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells Biol. Pharmaceut. Bull. 28 2005 2274 2278
20. G. Klopman, L.M. Shi, and A. Ramu Quantitative structure-activity relationship of multidrug resistance reversal agents Mol. Pharmacol. 52 1997 323 334
21. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug Deliv. Rev. 55 2003 53 81
22. V. Ling Multidrug resistance: molecular mechanisms and clinical relevance Cancer Chemother. Pharmacol. 40 1997 S3 S8
23. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson Autodock4 and autodocktools4: automated docking with selective receptor flexibility J. Comput. Chem. 30 2009 2785 2791
24. K. Noguchi, K. Katayama, J. Mitsuhashi, and Y. Sugimoto Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy Adv. Drug Deliv. Rev. 61 2009 26 33
25. I.K. Pajeva, and M. Wiese Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis) J. Med. Chem. 45 2002 5671 5686
26. H.L. Pearce, A.R. Safa, N.J. Bach, M.A. Winter, M.C. Cirtain, and W.T. Beck Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogues that modulate multidrug resistance Proc. Natl. Acad. Sci. U.S.A. 86 1989 5128 5132
27. H.L. Pearce, M.A. Winter, and W.T. Beck Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance Adv. Enzyme Regul. 30 1990 357 373
28. J.E. Penzotti, M.L. Lamb, E. Evensen, and P.D. Grootenhuis A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein J. Med. Chem. 45 2002 1737 1740
29. L.O. Regasini, I. Castro-Gamboa, D.H. Silva, M. Furlan, E.J. Barreiro, P.M. Ferreira, C. Pessoa, L.V. Lotufo, M.O. de Moraes, M.C. Young, and S. Bolzani Vda Cytotoxic guanidine alkaloids from Pterogyne nitens J. Nat. Prod. 72 2009 473 476
30. L.O. Regasini, M. Pivatto, L. Scorzoni, T. Benaducci, A. Fusco-Almeida, M. Giannini, E.J. Barreiro, D. Silva, and S. Bolzani Vda Antimicrobial activity of Pterogyne nitens Tul., Fabaceae, against opportunistic fungi Rev. Bras. Farmacogn. 20 2010 706 711
31. A. Sakurai, Y. Onishi, H. Hirano, M. Seigneuret, K. Obanayama, G. Kim, E.L. Liew, T. Sakaeda, K. Yoshiura, N. Niikawa, M. Sakurai, and T. Ishikawa Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1) Biochemistry 46 2007 7678 7693
32. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A. Mol, M.A. van der Valk, E.C. Robanus-Maandag, and H.P. te Riele et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502
33. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1981 1967 1972
34. K. Ueda, M.M. Cornwell, M.M. Gottesman, I. Pastan, I.B. Roninson, V. Ling, and J.R. Riordan The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein Biochem. Biophys. Res. Commun. 141 1986 956 962
35. T.K. Venkatachalam, S. Qazi, P. Samuel, and F.M. Uckun Inhibition of mast cell leukotriene release by thiourea derivatives Bioorg. Med. Chem. Lett. 13 2003 485 488
36. J.M. Zamora, H.L. Pearce, and W.T. Beck Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells Mol. Pharmacol. 33 1988 454 462